000813 德展健康
已收盘 11-22 15:00:00
资讯
新帖
简况
11月21日德展健康涨停分析:工业大麻,医美,新疆国企改革概念热股
证券之星 · 11-21 15:11
11月21日德展健康涨停分析:工业大麻,医美,新疆国企改革概念热股
德展健康最新公告:股东美林控股所持部分公司股份将被司法强制执行
证券之星 · 11-13
德展健康最新公告:股东美林控股所持部分公司股份将被司法强制执行
图解德展健康三季报:第三季度单季净利润同比减102.99%
证券之星 · 10-31
图解德展健康三季报:第三季度单季净利润同比减102.99%
A股NMN概念竞价活跃,美邦科技涨超17%,雅本化学涨超13%,金达威涨超8.5%,溢多利、众生药业、兄弟科技、德展健康等跟涨。
美港电讯 · 10-24
A股NMN概念竞价活跃,美邦科技涨超17%,雅本化学涨超13%,金达威涨超8.5%,溢多利、众生药业、兄弟科技、德展健康等跟涨。
【机构调研记录】金信基金调研德展健康
证券之星 · 09-27
【机构调研记录】金信基金调研德展健康
德展健康:9月26日接受机构调研,平安证券、财信证券等多家机构参与
证券之星 · 09-27
德展健康:9月26日接受机构调研,平安证券、财信证券等多家机构参与
德展健康最新公告:参股公司合作研发项目新适应症获得临床试验批准
证券之星 · 09-22
德展健康最新公告:参股公司合作研发项目新适应症获得临床试验批准
德展健康(000813.SZ)参股公司东方略合作研发项目新适应症获得临床试验批准
智通财经 · 09-22
德展健康(000813.SZ)参股公司东方略合作研发项目新适应症获得临床试验批准
德展健康最新公告:回购公司股份比例达到1%
证券之星 · 09-10
德展健康最新公告:回购公司股份比例达到1%
德展健康(000813.SZ)已耗资5381.42万元回购1%股份
智通财经 · 09-10
德展健康(000813.SZ)已耗资5381.42万元回购1%股份
德展健康:公司现阶段对于司美格鲁肽的布局规划为“原料药+制剂”
证券之星 · 09-06
德展健康:公司现阶段对于司美格鲁肽的布局规划为“原料药+制剂”
德展健康(000813)2024年中报简析:营收净利润同比双双增长
证券之星 · 08-29
德展健康(000813)2024年中报简析:营收净利润同比双双增长
德展健康(000813)6月30日股东户数5.1万户,较上期减少8.25%
证券之星 · 08-28
德展健康(000813)6月30日股东户数5.1万户,较上期减少8.25%
图解德展健康中报:第二季度单季净利润同比增386.06%
证券之星 · 08-28
图解德展健康中报:第二季度单季净利润同比增386.06%
德展健康(000813.SZ)发上半年业绩,净利润1015.26万元,同比扭亏为盈
智通财经 · 08-27
德展健康(000813.SZ)发上半年业绩,净利润1015.26万元,同比扭亏为盈
德展健康:VGX-3100临床试验入组工作仍在继续进行中,具体信息以东方略官网公告为准
证券之星 · 08-21
德展健康:VGX-3100临床试验入组工作仍在继续进行中,具体信息以东方略官网公告为准
华宝中证细分化工产业ETF联接A:连续4日下跌,累计跌幅3.58%
和讯网 · 08-15
华宝中证细分化工产业ETF联接A:连续4日下跌,累计跌幅3.58%
富国中证细分化工产业主题ETF基金更新《招募说明书》
同壁财经 · 08-09
富国中证细分化工产业主题ETF基金更新《招募说明书》
德展健康最新公告:申请强制执行47100万元
证券之星 · 08-08
德展健康最新公告:申请强制执行47100万元
德展健康:接受中金公司调研
每日经济新闻 · 08-06
德展健康:接受中金公司调研
加载更多
公司概况
公司名称:
德展大健康股份有限公司
所属行业:
医药制造业
上市日期:
1998-05-19
主营业务:
德展大健康股份有限公司主营业务为药品的研发、生产和销售,主要产品包括药品、美容肽原料、功能食品、护肤品等。2019年度,公司入选“中国上市企业市值500强”。公司子公司嘉林药业现跻身中国制药工业百强前50名,多次荣获中国化学制药行业工业企业综合实力百强称号,荣获北京市诚信创业企业、行业领军企业等荣誉。
发行价格:
4.57
{"stockData":{"symbol":"000813","market":"SZ","secType":"STK","nameCN":"德展健康","latestPrice":3.09,"timestamp":1732259022000,"preClose":3.26,"halted":0,"volume":140435584,"delay":0,"floatShares":2165000000,"shares":2165000000,"eps":0.0139,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.17,"latestTime":"11-22 15:00:00","open":3.28,"high":3.28,"low":3.06,"amount":444000000,"amplitude":0.0675,"askPrice":3.09,"askSize":233,"bidPrice":3.08,"bidSize":3734,"shortable":0,"etf":0,"ttmEps":0.0139,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":3.26,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":3.59,"lowLimit":2.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2164955990,"pbRate":1.36,"roa":"--","roe":"0.15%","epsLYR":0.0382,"committee":0.514622,"marketValue":6690000000,"floatMarketCap":6689000000,"peRate":222.302164,"changeRate":-0.0521,"turnoverRate":0.0649,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-11-25。"},"requestUrl":"/m/hq/s/000813","defaultTab":"news","newsList":[{"id":"2485322454","title":"11月21日德展健康涨停分析:工业大麻,医美,新疆国企改革概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485322454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485322454?lang=zh_cn&edition=full","pubTime":"2024-11-21 15:11","pubTimestamp":1732173101,"startTime":"0","endTime":"0","summary":"证券之星消息,德展健康11月21日涨停收盘,收盘价3.26元。该股于13点37分涨停,未打开涨停,截止收盘封单资金为3477.91万元,占其流通市值0.49%。11月21日的资金流向数据方面,主力资金净流入9349.11万元,占总成交额23.26%,游资资金净流出4187.84万元,占总成交额10.42%,散户资金净流出5161.27万元,占总成交额12.84%。近5日资金流向一览见下表:该股为工业大麻,医美,新疆国企改革概念热股,当日工业大麻概念上涨1.03%,医美概念上涨0.82%,新疆国企改革概念上涨0.63%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100018249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399974","BK0060","161026","000813","BK0114","BK0239"],"gpt_icon":0},{"id":"2483427889","title":"德展健康最新公告:股东美林控股所持部分公司股份将被司法强制执行","url":"https://stock-news.laohu8.com/highlight/detail?id=2483427889","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483427889?lang=zh_cn&edition=full","pubTime":"2024-11-13 22:30","pubTimestamp":1731508215,"startTime":"0","endTime":"0","summary":"德展健康公告,持股5%以上股东美林控股集团有限公司在华福证券开展的股票质押式回购业务发生违约,北京市第三中级人民法院要求华福证券通过集中竞价交易方式强制卖出美林控股所持公司21,399,184股股份(占其所持公司股份比例为7.29%1、占剔除公司回购专用账户股份数量后的公司总股本2比例为1.00%),强制执行期间为2024年11月18日至2024年11月28日。美林控股不是公司控股股东,其所持股份被司法强制执行不会导致公司控制权发生变化,不会对公司生产经营、公司治理产生不利影响。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300036221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000813","BK0239","BK0114","BK0060"],"gpt_icon":0},{"id":"2479875319","title":"图解德展健康三季报:第三季度单季净利润同比减102.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479875319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479875319?lang=zh_cn&edition=full","pubTime":"2024-10-31 02:07","pubTimestamp":1730311662,"startTime":"0","endTime":"0","summary":"证券之星消息,德展健康2024年三季报显示,公司主营收入3.54亿元,同比上升5.77%;归母净利润808.96万元,同比下降86.82%;扣非净利润461.12万元,同比上升123.13%;其中2024年第三季度,公司单季度主营收入1.06亿元,同比下降7.15%;单季度归母净利润-206.31万元,同比下降102.99%;单季度扣非净利润-329.1万元,同比上升70.35%;负债率2.63%,投资收益-1016.22万元,财务费用-5071.93万元,毛利率61.46%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100003201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000813"],"gpt_icon":0},{"id":"2477112635","title":"A股NMN概念竞价活跃,美邦科技涨超17%,雅本化学涨超13%,金达威涨超8.5%,溢多利、众生药业、兄弟科技、德展健康等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2477112635","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477112635?lang=zh_cn&edition=full","pubTime":"2024-10-24 09:27","pubTimestamp":1729733225,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0028","BK0191","BK0201","BK0077","BK0226","BK0239","002317","BK0070","BK0060","002626","159982","002562","BK0188","BK0229","300261","399300","000813","BK0114","BK0174","BK0197","300381","BK0186"],"gpt_icon":0},{"id":"2470671898","title":"【机构调研记录】金信基金调研德展健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2470671898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470671898?lang=zh_cn&edition=full","pubTime":"2024-09-27 08:02","pubTimestamp":1727395379,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及9月26日披露的机构调研信息,金信基金近期对1家上市公司进行了调研,相关名单如下:1)德展健康 个股亮点:公司在研的司美格鲁肽及重组胶原蛋白等项目涉及合成生物相关研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700005388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000813","BK0060","BK0114"],"gpt_icon":0},{"id":"2470750892","title":"德展健康:9月26日接受机构调研,平安证券、财信证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2470750892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470750892?lang=zh_cn&edition=full","pubTime":"2024-09-27 00:04","pubTimestamp":1727366653,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年9月26日德展健康发布公告称公司于2024年9月26日接受机构调研,平安证券、财信证券、金信基金、恒生前海基金、红土创新基金、惠通基金参与。WYY项目计划将于2024年底或2025年初完成IND申报,如有重大进展公司将及时履行信息披露义务。德展健康主营业务:药品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700000009.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000813","BK0060","BK0114","BK0239","161027"],"gpt_icon":0},{"id":"2469921983","title":"德展健康最新公告:参股公司合作研发项目新适应症获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2469921983","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469921983?lang=zh_cn&edition=full","pubTime":"2024-09-22 16:29","pubTimestamp":1726993794,"startTime":"0","endTime":"0","summary":"德展健康公告,参股公司东方略近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,批准了其与美国Inovio公司合作研发的VGX-3100项目针对HPV-16/18相关肛门癌前病变的II期临床试验申请。VGX-3100是东方略与Inovio公司在DNA免疫治疗领域的重点合作开发项目,用于治疗由人类乳头状瘤病毒导致的癌前病变。本次VGX-3100新获批的II期临床试验是针对肛门癌前病变,是国内首款进入II期临床试验的针对肛门癌前病变治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092200001584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000813","BK0239","BK0114","BK1141","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"2469213009","title":"德展健康(000813.SZ)参股公司东方略合作研发项目新适应症获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2469213009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469213009?lang=zh_cn&edition=full","pubTime":"2024-09-22 16:28","pubTimestamp":1726993697,"startTime":"0","endTime":"0","summary":"智通财经APP讯,德展健康(000813.SZ)公告,公司于近日收到公司参股公司北京东方略生物医药科技股份有限公司(简称“东方略”)的通知,东方略于近日收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》(编号 2024LP02122),批准了其与美国 Inovio Pharmaceuticals, Inc.(简称 “Inovio 公司”)合作研发的VGX-3100项目针对 HPV-16/18 相关肛门癌前病变的II期临床试验申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1185586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000813","03347","BK0114","BK1583","BK0239","BK1141","BK1576","BK0060"],"gpt_icon":0},{"id":"2466876444","title":"德展健康最新公告:回购公司股份比例达到1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2466876444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466876444?lang=zh_cn&edition=full","pubTime":"2024-09-10 18:00","pubTimestamp":1725962443,"startTime":"0","endTime":"0","summary":"德展健康公告,截至2024年9月10日,公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份21,649,500股,占公司目前总股本的1.00%,成交总金额5381.42万元(不含交易费用)。本次回购符合公司既定的股份回购方案及相关法律法规的要求。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091000029750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000813","BK0060","BK0114","BK0239"],"gpt_icon":0},{"id":"2466482419","title":"德展健康(000813.SZ)已耗资5381.42万元回购1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2466482419","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466482419?lang=zh_cn&edition=full","pubTime":"2024-09-10 17:55","pubTimestamp":1725962147,"startTime":"0","endTime":"0","summary":"智通财经APP讯,德展健康(000813.SZ)发布公告,截至2024年9月10日,公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份2164.95万股,占公司目前总股本的1%,最高成交价为2.54元/股,最低成交价为2.44元/股,成交总金额5381.42万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1181493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0114","BK0060","000813","BK0239"],"gpt_icon":0},{"id":"2465660451","title":"德展健康:公司现阶段对于司美格鲁肽的布局规划为“原料药+制剂”","url":"https://stock-news.laohu8.com/highlight/detail?id=2465660451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465660451?lang=zh_cn&edition=full","pubTime":"2024-09-06 19:01","pubTimestamp":1725620466,"startTime":"0","endTime":"0","summary":"针对贵司的“人源化胶原蛋白”公司表述在25年6月份将实现医药级产品上市的疑问同上。我国原料药生产审批采取备案制,制剂需经临床试验后注册上市。公司目前正在积极推进原料产品中试转化工作,先期计划形成原料产品销售,同时加速原料药产品上市,推进制剂产品研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090600033434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","000813","BK0114"],"gpt_icon":0},{"id":"2463443873","title":"德展健康(000813)2024年中报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2463443873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463443873?lang=zh_cn&edition=full","pubTime":"2024-08-29 06:18","pubTimestamp":1724883480,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期德展健康发布2024年中报。根据财报显示,德展健康营收净利润同比双双增长。截至本报告期末,公司营业总收入2.48亿元,同比上升12.46%,归母净利润1015.26万元,同比上升234.22%。按单季度数据看,第二季度营业总收入1.47亿元,同比上升71.71%,第二季度归母净利润2695.77万元,同比上升386.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900006454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000813"],"gpt_icon":0},{"id":"2462357004","title":"德展健康(000813)6月30日股东户数5.1万户,较上期减少8.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462357004","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462357004?lang=zh_cn&edition=full","pubTime":"2024-08-28 17:08","pubTimestamp":1724836110,"startTime":"0","endTime":"0","summary":"证券之星消息,近日德展健康披露,截至2024年6月30日公司股东户数为5.1万户,较3月31日减少4592.0户,减幅为8.25%。在化学制药行业个股中,德展健康股东户数高于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.24万户。从股价来看,2024年3月31日至2024年6月30日,德展健康区间跌幅为28.28%,在此期间股东户数减少4592.0户,减幅为8.25%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082800031781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0114","000813"],"gpt_icon":0},{"id":"2462112634","title":"图解德展健康中报:第二季度单季净利润同比增386.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2462112634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462112634?lang=zh_cn&edition=full","pubTime":"2024-08-28 02:08","pubTimestamp":1724782113,"startTime":"0","endTime":"0","summary":"证券之星消息,德展健康2024年中报显示,公司主营收入2.48亿元,同比上升12.46%;归母净利润1015.26万元,同比上升234.22%;扣非净利润790.21万元,同比上升189.44%;其中2024年第二季度,公司单季度主营收入1.47亿元,同比上升71.71%;单季度归母净利润2695.77万元,同比上升386.06%;单季度扣非净利润2580.25万元,同比上升348.97%;负债率2.56%,投资收益-785.6万元,财务费用-3411.38万元,毛利率60.77%。财报数据概要请见下图: 以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082800002591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000813"],"gpt_icon":0},{"id":"2462907911","title":"德展健康(000813.SZ)发上半年业绩,净利润1015.26万元,同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2462907911","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462907911?lang=zh_cn&edition=full","pubTime":"2024-08-27 23:49","pubTimestamp":1724773753,"startTime":"0","endTime":"0","summary":"智通财经APP讯,德展健康(000813.SZ)发布2024年半年度报告,报告期内公司实现营业收入2.48亿元,同比增长12.46%;归属于上市公司股东的净利润1015.26万元,同比扭亏为盈;归属于上市公司股东扣除非经常性损益净利润790.21万元,同比扭亏为盈;基本每股收益0.0047元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1172623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000813"],"gpt_icon":0},{"id":"2461247849","title":"德展健康:VGX-3100临床试验入组工作仍在继续进行中,具体信息以东方略官网公告为准","url":"https://stock-news.laohu8.com/highlight/detail?id=2461247849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461247849?lang=zh_cn&edition=full","pubTime":"2024-08-21 19:02","pubTimestamp":1724238147,"startTime":"0","endTime":"0","summary":"谢谢德展健康董秘:尊敬的投资者您好,东方略为公司参股公司,根据东方略官网公开信息显示,ABC-3100针对HPV感染引起的肛门/肛周癌前病变的临床试验申请已于近日提交,请咨询东方略公司了解详情。投资者:请问进行中VGX-3100临床试验入组人数已经达82人,是否超预期了?德展健康董秘:尊敬的投资者您好,VGX-3100临床试验入组工作仍在继续进行中,具体信息以东方略官网公告为准,谢谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100034103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK0060","BK1583","BK0239","BK1576","BK1141","BK0114","000813"],"gpt_icon":0},{"id":"2459449691","title":"华宝中证细分化工产业ETF联接A:连续4日下跌,累计跌幅3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459449691","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459449691?lang=zh_cn&edition=full","pubTime":"2024-08-15 01:12","pubTimestamp":1723655565,"startTime":"0","endTime":"0","summary":"8月14日,华宝中证细分化工产业主题ETF联接A遭遇2.33%的跌幅,最新净值显示为0.51元,这已是连续第四个下跌,累计跌幅达到3.58%。该基金自2021年6月成立以来,规模为0.26亿元,累计收益率为-49.17%。截至2023年末,基金的机构持有者持有0.10亿份,占21.97%,而个人投资者持有0.35亿份,占比78.03%。截至2024年6月30日,华宝中证细分化工产业主题ETF联接A的前十持仓占比合计为0.10%,主要持仓包括万华化学、华鲁恒升、宝丰能源等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081505430195994e42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081505430195994e42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["000813","BK0239","BK0114","BK0060","516690"],"gpt_icon":0},{"id":"2458403596","title":"富国中证细分化工产业主题ETF基金更新《招募说明书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2458403596","media":"同壁财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458403596?lang=zh_cn&edition=full","pubTime":"2024-08-09 21:43","pubTimestamp":1723211031,"startTime":"0","endTime":"0","summary":"8月9日,富国中证 细分化工 产业主题交易型开放式指数证券投资基金更新《招募说明书》。富国中证细分化工产业主题交易型开放式指数证券投资基金已于2021年2月3日获得中国证监会准予注册的批复。该基金的基金合同于2021年3月1日生效。据了解,该基金管理人为富国基金管理有限公司,基金托管人为中国 建设银行 股份有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809214831958c0568&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240809214831958c0568&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["000813.SH","BK0239","000813","BK0114","BK0060"],"gpt_icon":0},{"id":"2457363471","title":"德展健康最新公告:申请强制执行47100万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457363471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457363471?lang=zh_cn&edition=full","pubTime":"2024-08-08 16:27","pubTimestamp":1723105654,"startTime":"0","endTime":"0","summary":"德展健康公告,由于长江脉重组事项进展缓慢且戴彦榛仍未履行给付义务或给出切实可行的还款计划,公司于近日向北京市第三中级人民法院提出了强制执行申请。申请事项包括请求戴彦榛支付欠付的投资款及违约金47,100万元,以及逾期付款违约金等。公司已对应收戴彦榛债权计提了1.48亿元的坏账准备,后续将根据执行进展情况进行账务处理。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080800031715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0060","BK0239","000813"],"gpt_icon":0},{"id":"2457128220","title":"德展健康:接受中金公司调研","url":"https://stock-news.laohu8.com/highlight/detail?id=2457128220","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457128220?lang=zh_cn&edition=full","pubTime":"2024-08-06 18:46","pubTimestamp":1722941210,"startTime":"0","endTime":"0","summary":"每经AI快讯,德展健康发布公告称,2024年8月6日上午10:00-11:30,德展健康接受中金公司调研,公司副总经理、董事会秘书肖建峰,投资者关系专员赵文佳参与接待,并回答了调研机构提出的问题。每经头条(nbdtoutiao)——日本加息魔咒!金融风暴将至?历史上日本加息后多爆发全球金融风暴:2000年科网股破灭,2007年次贷危机(记者 曾健辉)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061847209f13ce68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061847209f13ce68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03908","601995","BK0276","BK0239","000813","BK0060","BK0114"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-05-19","address":"新疆维吾尔自治区乌鲁木齐市天山区金银路53号金融大厦1611室","stockEarnings":[{"period":"1week","weight":0.0692},{"period":"1month","weight":0.0692},{"period":"3month","weight":0.3553},{"period":"6month","weight":0.207},{"period":"1year","weight":-0.158},{"period":"ytd","weight":-0.055}],"companyName":"德展大健康股份有限公司","boardCode":"AI0027","perCapita":"42411股","boardName":"医药制造业","registeredCapital":"216495万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 德展大健康股份有限公司主营业务为药品的研发、生产和销售,主要产品包括药品、美容肽原料、功能食品、护肤品等。2019年度,公司入选“中国上市企业市值500强”。公司子公司嘉林药业现跻身中国制药工业百强前50名,多次荣获中国化学制药行业工业企业综合实力百强称号,荣获北京市诚信创业企业、行业领军企业等荣誉。","serverTime":1732328262695,"listedPrice":4.57,"stockholders":"51038人(较上一季度增加0.01%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德展健康(000813)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德展健康(000813)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德展健康,000813,德展健康股票,德展健康股票老虎,德展健康股票老虎国际,德展健康行情,德展健康股票行情,德展健康股价,德展健康股市,德展健康股票价格,德展健康股票交易,德展健康股票购买,德展健康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德展健康(000813)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德展健康(000813)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}